JP2021534185A5 - - Google Patents
Info
- Publication number
- JP2021534185A5 JP2021534185A5 JP2021507918A JP2021507918A JP2021534185A5 JP 2021534185 A5 JP2021534185 A5 JP 2021534185A5 JP 2021507918 A JP2021507918 A JP 2021507918A JP 2021507918 A JP2021507918 A JP 2021507918A JP 2021534185 A5 JP2021534185 A5 JP 2021534185A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- subject
- composition according
- statin
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862719404P | 2018-08-17 | 2018-08-17 | |
| US62/719,404 | 2018-08-17 | ||
| PCT/US2019/046710 WO2020037153A1 (en) | 2018-08-17 | 2019-08-15 | Methods of reducing the need for peripheral arterial revascularization in a statin-treated subject |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021534185A JP2021534185A (ja) | 2021-12-09 |
| JP2021534185A5 true JP2021534185A5 (cg-RX-API-DMAC7.html) | 2022-08-22 |
Family
ID=69524891
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507918A Pending JP2021534185A (ja) | 2018-08-17 | 2019-08-15 | スタチン治療対象における末梢動脈血行再建の必要性を低減する方法 |
Country Status (17)
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX377553B (es) | 2009-04-29 | 2025-03-10 | Amarin Pharma Inc | Composicion farmaceutica estable y metodos de uso de la misma. |
| CN107233337A (zh) | 2009-04-29 | 2017-10-10 | 阿马里纳药物爱尔兰有限公司 | 含有epa和心血管剂的药物组合物以及使用其的方法 |
| BRPI1011883A2 (pt) | 2009-06-15 | 2016-09-13 | Amarin Pharma Inc | uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina |
| NZ599061A (en) | 2009-09-23 | 2014-05-30 | Amarin Pharmaceuticals Ie Ltd | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
| US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| NZ744990A (en) | 2010-11-29 | 2019-10-25 | Amarin Pharmaceuticals Ie Ltd | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
| US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
| EP2800469B1 (en) | 2012-01-06 | 2021-08-25 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |
| US9603826B2 (en) | 2012-06-29 | 2017-03-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| WO2014074552A2 (en) | 2012-11-06 | 2014-05-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
| US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
| US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
| US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
| US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
| US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
| US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
| US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
| US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
| WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
| US10966951B2 (en) | 2017-05-19 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
| US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
| US12430998B2 (en) | 2018-09-14 | 2025-09-30 | Avive Solutions, Inc. | Device based responder network activation and virtual assistant integration |
| US11640755B2 (en) | 2018-09-14 | 2023-05-02 | Avive Solutions, Inc. | Real time defibrillator incident data |
| US11645899B2 (en) | 2018-09-14 | 2023-05-09 | Avive Solutions, Inc. | Responder network |
| MA50490A (fr) | 2018-09-24 | 2020-09-02 | Amarin Pharmaceuticals Ie Ltd | Procédés de réduction du risque d'événements cardiovasculaires chez un sujet |
| CA3160676A1 (en) | 2019-11-12 | 2021-05-20 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter |
| US20210153817A1 (en) * | 2019-11-21 | 2021-05-27 | Avive Solutions, Inc. | Device based responder network activation and virtual assistant integration |
| US11986452B2 (en) | 2021-04-21 | 2024-05-21 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
| EP4329742A4 (en) * | 2021-04-29 | 2025-02-26 | Amarin Pharmaceuticals Ireland Limited | COMPOSITIONS COMPRISING EPA AND METHODS OF USE THEREOF FOR TREATING AND/OR PREVENTING ENDOTHELIAL DYSFUNCTION IN A SUBJECT |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090239927A1 (en) * | 2004-12-06 | 2009-09-24 | George Bobotas | Statin and Omega-3 Fatty Acids For Lipid Therapy |
| JP2009544701A (ja) * | 2006-07-21 | 2009-12-17 | リライアント・ファーマシューティカルズ・インコーポレイテッド | オメガ3脂肪酸を含む組成物、ならびに末梢動脈障害および間欠性跛行を処置するためのそれらの使用 |
| US9603826B2 (en) * | 2012-06-29 | 2017-03-28 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy |
| US20140322314A1 (en) * | 2013-04-29 | 2014-10-30 | Matinas Biopharma, Inc. | Omega-3 Fatty Acid Formulations for Use as Pharmaceutical Treatment |
| CN114558129A (zh) * | 2014-03-17 | 2022-05-31 | 赛诺菲生物技术公司 | 用于降低心血管风险的方法 |
| US10406130B2 (en) * | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
| PT3275438T (pt) * | 2016-07-29 | 2021-01-25 | Kowa Co | Métodos de prevenção de eventos cardiovasculares em populações dislipidémicas de risco residual |
-
2019
- 2019-08-15 US US17/275,576 patent/US20220362200A1/en not_active Abandoned
- 2019-08-15 MX MX2021001906A patent/MX2021001906A/es unknown
- 2019-08-15 EA EA202190547A patent/EA202190547A1/ru unknown
- 2019-08-15 JP JP2021507918A patent/JP2021534185A/ja active Pending
- 2019-08-15 MA MA52680A patent/MA52680A1/fr unknown
- 2019-08-15 EP EP19849946.9A patent/EP3836914A4/en active Pending
- 2019-08-15 SG SG11202101562UA patent/SG11202101562UA/en unknown
- 2019-08-15 CN CN201980069084.5A patent/CN112912071A/zh active Pending
- 2019-08-15 TN TNP/2021/000028A patent/TN2021000028A1/en unknown
- 2019-08-15 AU AU2019321568A patent/AU2019321568B2/en active Active
- 2019-08-15 KR KR1020217007524A patent/KR20210047312A/ko not_active Ceased
- 2019-08-15 WO PCT/US2019/046710 patent/WO2020037153A1/en not_active Ceased
- 2019-08-15 BR BR112021002884-6A patent/BR112021002884A2/pt not_active Application Discontinuation
-
2021
- 2021-02-04 IL IL280643A patent/IL280643A/en unknown
- 2021-02-16 NI NI202100009A patent/NI202100009A/es unknown
- 2021-02-16 CL CL2021000400A patent/CL2021000400A1/es unknown
- 2021-02-16 PH PH12021550328A patent/PH12021550328A1/en unknown
- 2021-12-03 CL CL2021003221A patent/CL2021003221A1/es unknown
- 2021-12-03 CL CL2021003222A patent/CL2021003222A1/es unknown
-
2024
- 2024-08-21 US US18/810,687 patent/US20250186386A1/en active Pending
-
2025
- 2025-04-22 AU AU2025202801A patent/AU2025202801A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11179362B2 (en) | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy | |
| JP2020128412A5 (cg-RX-API-DMAC7.html) | ||
| HRP20210686T1 (hr) | Pripravci i postupci za liječenje moždanog udara kod subjekta na istodobnoj terapiji statinom | |
| US10966951B2 (en) | Compositions and methods for lowering triglycerides in a subject having reduced kidney function | |
| US20200268702A1 (en) | Methods of treating hypertriglyceridemia | |
| CA3008079C (en) | Use of eicosapentaenoic acid to treat hypertriglyceridemia | |
| US20200108041A1 (en) | Methods of reducing ldl-p | |
| US20140221676A1 (en) | Compositions and methods for treating and/or preventing cardiovascular disease | |
| US20150250757A1 (en) | Methods for treating hypertriglyceridemia | |
| US20140004183A1 (en) | Methods for treating cardiovascular disease in statin-tolerant subjects | |
| Nissen | When is a placebo not a placebo | |
| ES2524596T3 (es) | Tratamiento a largo plazo de la insuficiencia cardiaca sintomática | |
| Savelieva et al. | Polyunsaturated fatty acids for prevention of atrial fibrillation: a ‘fishy'story | |
| TH2101000853A (th) | องค์ประกอบสำหรับใช้ในการลดความจำเป็นสำหรับการมีเลือดมาเลี้ยงใหม่ที่หลอดเลือดแดงส่วนปลายในผู้รับการทดลองที่ได้รับการรักษาด้วยสแตติน | |
| HK40036364A (en) | Compositions comprising eicosapentaenoic acid for treating myocardial infarction in a subject on concomitant statin therapy | |
| Mihaiu et al. | Experimental Studies on Guinea Pig Regarding the Influence of Polyunsaturated Fatty Acids as Enhancer in Statin Medication | |
| AU2016231552A1 (en) | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia | |
| HK1169838A (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| HK1169838B (en) | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy | |
| HK1203764B (en) | Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject |